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Germline mutations of the tumour suppressor gene BRCA1 are involved in the predisposition and development of breast cancer and
account for 20–45% of all hereditary cases. There is an increasing evidence that these tumours are characterised by a specific
phenotype and pattern of gene expression. We have hypothesised that differences in chemosensitivity might parallel molecular
heterogeneity of hereditary and sporadic breast tumours. To this end, we have investigated the chemosensitivity of the BRCA1-
defective HCC1937 breast cancer cell line, and the BRCA1-competent MCF-7 (hormone-sensitive) and MDA-MB231 (hormone-
insensitive) breast cancer cell lines using the MTT assay. The 50% inhibitory concentration (IC50) for the individual compounds were
derived by interpolate plot analysis of the logarithmic scalar concentration curve after a 48h exposure. HCC1937 cells were
significantly (Po0.005) more sensitive to cisplatin (CDDP) (IC50:3 0 – 4 0mM) compared with MCF-7 (IC50:6 0 – 7 0mM) and MDA-
MB231 (IC50: 90–100mM) cells. On the other hand, BRCA1-defective breast cancer cells were significantly less sensitive to
doxorubicin (Dox) (IC50:4 5–5 0mM) compared with MCF-7 (IC50:1–5mM) and MDA-MB231 (IC50:5–10mM)( Po0.02), as well as
to paclitaxel (Tax) (IC50: 42mM for HCC1937, 0.1–0.2mM for MCF-7 and 0.01–0.02mM for MDA-MB231) (Po0.001). Full-length
BRCA1 cDNA transfection of BRCA1-defective HCC1937 cells led to the reconstituted expression of BRCA1 protein in
HCC1937/
WTBRCA1-derived cell clone, but did not reduce tumour cell growth in soft agar. BRCA1 reconstitution reverted the
hypersensitivity to CDDP (Po0.02), and restored the sensitivity to Dox (Po0.05) and Tax (Po0.001), compared with parental
HCC1937 cells. Taken together, our findings suggest a specific chemosensitivity profile of BRCA1-defective cells in vitro, which is
dependent on BRCA1 protein expression, and suggest prospective preclinical and clinical investigation for the development of
tailored therapeutical approaches in this setting.
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Breast carcinoma is the most important malignant disease for
Western women. An hereditary form has been identified, which is
related to inherited cancer-predisposing germline mutations.
Germline mutations of BRCA1 gene have been identified in
15–20% of women with a family history of breast cancer and 60–
80% with family history of both breast and ovarian cancer
(Nathanson et al, 2001).
The human BRCA1 gene, which was mapped in 1990 and was
subsequently cloned in 1994 (Miki et al, 1994), is located at 17q21,
and encodes a nuclear phosphoprotein of 1863 amino acids that
contains several functional domains (Chen et al, 1996). These
domains interact with numerous molecules, including DNA
damage-repair proteins and other proteins with a regulatory role
in fundamental cellular processes (Deng and Brodie, 2000). In fact,
BRCA1 participates in a number of functions, including the
regulation of cell proliferation and in the events that require
chromatin remodelling (Hu et al, 1999; Bochar et al, 2000).
Overexpression of the BRCA1 gene interferes with breast cancer
cell growth in vitro (Holt et al, 1996) and may induce apoptosis if
overexpressed in transfected cancer cells (Shao et al, 1996),
supporting the hypothesis that BRCA1 is a tumour suppressor
gene.
Recent reports have highlighted the role of BRCA1 in
maintaining the genomic integrity and regulating sensitivity to
DNA-damaging agents. BRCA1 becomes activated by phosphor-
ylation and localises after exposure to DNA double-strand break
damage (Scully et al, 1997a). It interacts with Rad51 and BRCA2 in
subnuclear foci, and activates the recombination repair process
(Scully et al, 1997b; Chen et al, 1999). Using isogenic mouse
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sembryonic stem cell lines, it has been demonstrated that BRCA1 is
required for the formation of subnuclear Rad51 complexes in
response to cellular damage by ionising radiation or cisplatin
(CDDP) treatment, suggesting that BRCA1 contributes to damage
repair and/or tolerance by promoting assembly of the Rad51
complex (Bhattacharyya et al, 2000). It has been shown that
upregulation of BRCA1 expression leads to increased resistance to
CDDP in ovarian cancer cells (Husain et al, 1998). It has also been
shown that restoration of BRCA1 expression in the BRCA1-
defective HCC1937 human breast cancer cell line induces radio-
resistance (Abbott et al, 1999). Anti-BRCA1 ribozymes led to
increased sensitivity to the DNA-damaging agents CDDP and
etoposide, and to resistance to the microtubule-interfering agents
paclitaxel (Tax) and vincristine (Lafarge et al, 2001). In this cell
system, the molecular mechanism of resistance to microtubule-
interfering agents was correlated to transcriptional changes in
genes involved in the c-Jun NH(2)-terminal kinase (JNK) pathway.
More recently, it has been reported that the expression of a
truncated BRCA1 mutant with a dominant-negative activity
modifies chemosensitivity in a mouse ovarian cancer cell line
(Sylvain et al, 2002). Taken together, these findings suggest that
changes in the sensitivity to antitumor agents could indeed be a
part of the phenotype of breast carcinomas arising in the
hereditary setting and could be of relevance in the treatment of
these tumours.
We investigated the effects of BRCA1 inactivation on drug
sensitivity in human breast cancer cell lines. We asked whether
human breast cancer cells derived from an individual harbouring
a BRCA1 germline mutation and complete loss of BRCA1 function
(BRCA
/) would have a specific chemosensitivity profile
compared to the sporadic tumour-derived hormone-sensitive
MCF-7 and hormone-insensitive MDA-MB231 cell lines. We
reasoned that BRCA
/ breast cancer cells offer the specific
molecular pathology milieu for experimentally addressing the
issues relevant to the management of breast tumours in the
hereditary setting. The specific role of BRCA1 in determining drug
sensitivity was also investigated by comparative analysis of
parental HCC1937 with HCC1937/
WTBRCA1-derived cell line with
reconstitued BRCA1 protein expression after BRCA1 full-length
cDNA transfection.
MATERIALS AND METHODS
Cell cultures and reagents
HCC1937, MCF-7 and MDA-MB231 cell lines were purchased from
the American Type Culture Collection (Rockville, MD, USA).
HCC1937 cells were grown in RPMI 1640 medium (Life
Technologies, Paisley, UK), while MCF-7 and MDA-MB231 were
grown in Dulbecco’s modified Eagle’s medium (DMEM) (Life
Technologies). All media were supplemented with 10% fetal bovine
serum (FBS), 2mML -glutamine, 100mgml
1 streptomycin and
100Uml
1 penicillin. All cell lines were cultured at a constant
temperature of 371C in a 5% carbon dioxide (CO2) humidified
atmosphere. HCC1937 transfected with full-length BRCA1 cDNA
cells (HCC1937/
WTBRCA1) were generated in this laboratory.
CDDP and Tax were purchased from Bristol-Myers Squibb (NJ,
USA). Doxorubicin (Dox) was purchased from Pharmacia &
Upjohn (Dublin, Ireland).
Drug sensitivity assays
Cell proliferation analysis was performed on breast cancer cells in
the presence of increasing concentrations of antitumour drugs by
the thiazolyl blue (MTT) assay. Briefly, breast cancer cells
(110
4well
1) were plated in 96-well plates. At 24h after the
initial seeding of the cells, various drug treatments were carried
out for 48h. Subsequently, the wells were incubated with
10mlwell
1 of MTT at 5mgml
1 (Sigma Chemical Co., St Louis,
MO, USA) for 1h at 371C. Then 100ml of 0.04 N HCl in isopropanol
was added and the absorbance was measured in a microplate
reader at a wavelength of 620nm. A value of 100% was assigned to
untreated control cultures, and the concentration of drug that
reduced the number of viable cells to 50% after 48h of exposure
(IC50) was derived by an interpolate logaritmic concentration
curve. Results were derived from at least three independent sets of
triplicate experiments.
cDNA transfection
Parental HCC1937 were transfected with a pcDNA 3.1 plasmid
containing the full-length BRCA1 gene. Stable transfectants were
selected and used for drug sensitivity assays. For stable transfec-
tions, cells at 30–40% confluency were incubated overnight with
2mg of plasmid DNA, using the FuGENE 6 transfection reagent
(Roche Molecular Biochemicals, Monza, Italy) according to the
manufacturer’s instructions. Cells were then selected in G418
(0.4mgml
1) (Invitrogen Life Technologies, La Jolla, CA, USA). Cell
clones that stably expressed G418 and retained growth potential
were assayed for BRCA1 expression by Western blot assay.
Western Blot analysis of BRCA1 protein
Protein extracts were prepared as described elsewhere (Faniello
et al, 1999) and equal amounts (50mg) were resolved by SDS–
polyacrylamide gel electrophoresis and transferred to nitrocellu-
lose membranes (Hybond ECL Nitrocellulose Membrane, Amer-
sham Pharmacia Biotech, Piscataway, NJ, USA). After addition of
the blocking mixture, the membrane was incubated with a 1:200
dilution of BRCA1 D9 mouse monoclonal IgG2a antibody for 2h at
room temperature. Bound antibody was detected using a 1:2000
dilution of HRP-conjugated goat anti-mouse IgG antibody for 1h
at room temperature. All the antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). The signal was
detected using ECL (Santa Cruz Biotechnology, Santa Cruz, CA,
USA).
Soft agar growth assay
Soft agar assay was performed using 510
4 HCC1937 parental
cells, mock-transfected HCC1937 cells and HCC1937/
WTBRCA1
cells, assayed for BRCA1 protein expression. They were suspended
in 1.5ml of 3% Noble Agar (Difco, Kansas City, MO, USA), 100mM
triptose phosphate buffer (Difco, USA), 10% FBS RPMI 1640
medium and layered on 7ml of a similar buffer with Noble Agar
concentration increased to 5% in 60mm culture dishes. Plates were
incubated at a constant temperature of 371C with a humidified
atmosphere of 5% CO2 for 4 weeks, stained with crystal violet and
scored for colonies that were greater than 60mm.
Flow cytometric analysis of apoptosis
Apoptotic cell death was analysed by the Annexin-V kit
(MedSystems Diagnostics, Vienna, Austria). Briefly, cells were
incubated with Annexin-V-FITC in binding buffer (provided by
the manufacturer) for 10min at room temperature, washed and
resuspended in the same buffer as described by the manufacturer.
Analysis of apoptosis was performed by flow cytometry (FACScan,
Becton Dickinson, San Jose `, CA, USA).
Statistical analysis
Results are expressed as mean7s.d. The statistical significance of
differences between the experimental groups was analysed using
the t-test; differences were considered significant when Pp0.05.
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sRESULTS
Differential sensitivity of HCC1937, MCF-7 and
MDA-MB231 cell lines to cytotoxic drugs
We examined the differences in the sensitivity of the HCC1937
human breast cancer cell line harbouring a BRCA1 mutation and
with complete loss of BRCA1 function, compared with hormone-
sensitive MCF-7 and hormone-insensitive MDA-MB231 cell lines,
to chemotherapeutic agents that are commonly used in the
treatment of breast cancer.
Treatment with the DNA alkylating and crosslinking agent
CDDP (1–100mM) produced a dose-dependent reduction in cell
growth in all cell lines after 48h of treatment (Figure 1A–C).
However, the HCC1937 (BRCA1-defective) cell line was 2–3-fold
more sensitive to CDDP compared with BRCA1-competent cell
lines, with an IC50 in a range of 30–40mM drug concentration
(Figure 1D). MCF-7 and MDA-MB231 cells showed significantly
higher IC50’s, which were in the range of 60–70 and 90–100mM,
respectively (Figure 1D).
The treatment of these cells with the DNA helix intercalator and
topoisomerase II inhibitor Dox or with the mitotic spindle poison
Tax showed an opposite pattern of chemosensitivity compared
with CDDP. Increasing doses of Dox (1–100mM) produced a
progressive reduction in cell growth in all cell lines after 48h
(Figure 2A–C). HCC1937 cells were resistant to Dox, with an IC50
in the range of 45–50mM. Compared with the other cell lines,
HCC1937 cells are approx 5–10-fold more resistant (Figure 2D). In
fact, the MCF-7 and MDA-MB231 cells showed lower IC50
concentrations and were in a range of 1–5 and 5–10mM,
respectively (Figure 2D).
We then studied the effect of Tax on BRCA1-defective and
BRCA1-competent cancer cells. Tax is an active microtubule-
interfering agent for the treatment of advanced breast cancer.
Figure 3 shows the differential response of these breast cancer cell
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Figure 1 Differential sensitivity among BRCA1-defective and BRCA1-
competent cells to CDDP. In (A) HCC1937 cells, (B) MCF-7 cells and (C)
MDA-MB231 cells, the dose-related activity of CDDP is shown as tumour
cell growth. Analysis was performed after 48h exposure to the drug and
the IC50 was calculated by interpolate logarithmic curve. In (D), the value of
IC50 determined for each cell line is shown. 1 and 11: Po0.005.
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Figure 2 Differential sensitivity among BRCA1-defective and BRCA1-
competent cells to Dox. In (A) HCC1937 cells, (B) MCF-7 cells and (C)
MDA-MB231 cells, the dose-related activity of Dox is shown. Interpolate
logarithmic curve and the IC50 of cell growth are shown in each quadrant.
In (D), the value of IC50 determined for each cell line is shown. 1 and 11:
Po0.02.
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Figure 3 Differential sensitivity among BRCA1-defective and BRCA1-
competent cells to Tax. In (A) HCC1937 cells, (B) MCF-7 cells and (C)
MDA-MB231 cells, the dose-related activity of Tax is shown. Interpolate
logarithmic curve and the IC50 of cell growth are shown in each quadrant.
In (D), the value of IC50 determined for each cell line is shown. *:
Maximum of concentration used, no IC50 was achieved at this dose of drug.
1 and 11: Po0.001.
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slines to Tax-induced cytotoxicity. MCF-7 and MDA-MB231 cells
were highly sensitive to Tax (IC50: 0.1–0.2mM and 0.01–0.02mM,
respectively) (Figure 3B and C), whereas the HCC1937 cells showed
substantial resistance (Figure 3A). In fact, no IC50 concentration
was detected at doses inducing growth arrest in the other cell lines
even at 20-fold higher doses (2mM) (Figure 3D). These results
indicate that BRCA1-defective breast cancer cells are highly
responsive to CDDP treatment but resistant to Dox or Tax,
suggesting a differential pattern of chemosensitivity specific for
breast cancer cells with loss of BRCA1 function.
Western blot analysis of BRCA1 expression and
clonogenic soft agar growth of stable transfectants
HCC1937/
WTBRCA1
To demonstrate that this chemosensitivity profile is indeed
associated with the functional activity of the BRCA1 gene, we
generated full-length cDNA transfectants in order to perform
comparative chemosensitivity assays and apoptotic analysis
between BRCA1-defective and restored cells. By Western blot
analysis, we evaluated the restoration of BRCA1 expression in the
G418/resistant cDNA/transfectant cells. Figure 4 shows increased
expression of BRCA1 protein in transfected cells, suggesting
effective restoration of protein expression. Specificity of mAb used
for Western blot analysis has been further demonstrated in our
laboratory by its capacity of immunoprecipitating BRCA1 protein
which was capable of interacting with BASC protein (Quaresima
et al, manuscript in preparation). The stable transfectant was
therefore defined HCC1937/
WTBRCA1. In order to demonstrate
growth potential and maintenance of the malignant phenotype,
parental HCC1937, HCC1937/pcDNA3 (empty vector transfected)
and HCC1937/
WTBRCA1 were assayed for clonogenic soft agar
growth. No significant changes in the number and dimension
of colonies were observed (data not shown). While BRCA1
transfection is generally considered to inhibit breast cancer growth
by itself (Holt et al, 1996), it is possible to argue that our
experimental conditions and selection allows the isolation of
cellular clones insensitive to the growth-suppressing effect of a
functional BRCA1 gene. We considered that for the purpose of
comparative drug sensitivity evaluation, transfectants retaining an
analogous growth potential as compared to the unreconstituted
counterpart should be necessary. Stable BRCA1 transfectants HCC-
1937 have been successfully generated by the use of wild-type gene
inserted into different vectors (Ruffner et al, 2001; Andrews et al,
2002). Moderate increase of BRCA1 expression after transfection of
a full-lenght construct under a Tet-inducible promoter did not
affect the growth of BRCA1 wild-type MDA MB 435 (Mullan et al,
2001).
Full-length transfection of BRCA1 in HCC1937 induces
resistance to CDDP and restores sensitivity to Dox and Tax
HCC1937 cells and the HCC1937/
WTBRCA1 cells were analysed in
parallel for drug-sensitivity assays. Figure 5A–C shows that
HCC1937/
WTBRCA1 cells were less sensitive to the CDDP, and
the IC50 concentration increased significantly (Po0.02) in
HCC1937/
WTBRCA1 cells, suggesting that BRCA1 may be involved
in the repair process after the DNA damage induced by CDDP. On
the other hand, reintroduced BRCA1 expression restored sensitiv-
ity to Dox and Tax. The IC50 concentration of Dox was
significantly (Po0.05) lower in HCC1937/
WTBRCA1 compared
with the parental cells. HCC1937/
WTBRCA1 cells treated with Tax
also showed restored sensitivity to the drug. The IC50 in
HCC1937/
WTBRCA1 was in the range of 0.4–0.5mM, and the
difference between these cells and the parental HCC1937 cells was
significant (Po0.001).
Effects of BRCA1 restoration on drug-induced apoptotic
cell death
In order to evaluate whether BRCA1 restoration might influence
the apoptotic effects induced by cytotoxic drugs, we performed
apoptotic assays on HCC1937 and HCC1937/
WTBRCA1 cells
(Figure 6). Cells were treated for 48h at the IC50-specific drug
concentration, as measured for the most sensitive cell line, and
apoptosis was detected by Annexin-V analysis. Induction of
apoptotic cell death was detected in HCC1937 cells exposed to
CDDP (30mM) and Dox (50mM). A weaker apoptotic effect was seen
in HCC1937 exposed to Tax (2mM). Restoration of BRCA1
expression in HCC1937/
WTBRCA1 cells resulted in a dramatic
reduction of cell death induced by CDDP, whereas the majority of
cells underwent apoptosis after exposure to Tax. A detectable
increase in apoptotic events was also seen after exposure of
HCC1937/
WTBRCA1 cells to Dox. These data indicate that loss of
BRCA1 function also influences the apoptotic response of breast
cancer cells to cytotoxic drugs. However, flow cytometric analysis
of Annexin-V detects early events in cells committed to
programmed cell death, and therefore quantitative analysis of
apoptosis is not precisely equivalent to the growth inhibition
measured at a given time point.
DISCUSSION
In this study, we have demontrated that BRCA1-defective breast
cancer cells show a different sensitivity profile to anticancer drugs
such as CDDP, Dox or Tax when compared with BRCA1-
competent cells. These drugs are important cytotoxic agents for
the therapy of breast cancer, both in the adjuvant setting and/or
for the treatment of advanced disease. In our model, BRCA1-
defective cells displayed a significant higher sensitivity to CDDP,
whereas BRCA1 reconstitution significantly modified growth
inhibition and apoptosis induction, supporting the idea that
CDDP-induced DNA damage is strongly associated with the
inactivation of BRCA1. These data are consistent with other
observations demonstrating that inhibition of BRCA1 results in an
increased sensitivity to CDDP (Lafarge et al, 2001). Even though
the precise role of platinum compounds in the treatment of breast
cancer remains to be defined, the interest for this class of drugs has
been reawakened recently in the light of potential synergy with
newer agents (Martin, 2001). CDDP is an active drug that can be
safely and effectively combined with other recently introduced
agents, such as vinorelbine, gemcitabine, Tax and docetaxel.
Therefore, the possibility that hereditary breast tumours may
specifically be more sensitive to this drug is highly suggestive.
The treatment of BRCA1-defective breast cancer cells with Dox
or Tax in vitro showed an opposite response. Dox is a DNA helix
intercalator and topoisomerase II inhibitor, and plays a funda-
mental role in the management of breast cancer, both as single
agent as well as in combination with other drugs. Dox is
considered the most active single agent in breast cancer. The
potential resistance of hereditary breast tumors to Dox is an
important issue considering the frequent use of this drug in the
disease and the specific toxicity profile of anthracycline
HCC1937 HCC 1937/ 
WTBRCA1
MCF-7
BRCA1 220kDa
Figure 4 cDNA transfection reconstitutes BRCA1 expression. Western
blot analysis of BRCA1 protein expression in HCC1937, HCC-
1937/
WTBRCA1 and MCF-7 cells.
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late-onset ventricular dysfunction (Conte et al, 2000).
Recent reports in an experimental tumour cell system (Brodie
et al, 2001) and also based on clinical observations (Kloos et al,
2001) appear to show conflicting results indicating that BRCA1
inactivation might indeed result in increased doxorubicin sensi-
tivity. It has to be considered that the preclinical study involves
BRCA1 conditional knockout mice, a clearly different situation as
compared to human tumour cells, which might result from a
different carcinogenetic process. The clinical study refers to
doxorubicin-based combination chemotherapy, which also in-
volves cyclophosphamide and 5 fluorouracil and it is therefore not
possible to define the net role of doxorubicin in this setting. All
these findings have, however, to be considered in the interpreta-
tion of our results. Lafarge et al have demonstrated that inhibition
of BRCA1 led to enhanced sensitivity to etoposide that like Dox is a
topoisomerase II inhibitor (Lafarge et al, 2001). This discrepancy
could be because of the specific changes in other determinants of
Dox and/or etoposide, that is, increased cellular drug clearance.
Similar to Dox, the mitotic spindle poison Tax showed lower
activity in BRCA1-defective cells when compared to BRCA1 wild-
type cells, and the BRCA1 reconstitution dramatically reverted this
specific profile, inducing sensitivity to Tax. These findings on Tax
activity in BRCA1-defective breast cancer cells are consistent with
other studies that have reported interference of BRCA1 expression
with the antitumour effects induced by antimicrotubule agents in
cells derived from sporadic breast tumours (Lafarge et al, 2001;
Mullan et al, 2001). It is important to consider that Dox and Tax
have been combined together in the treatment of breast cancer
with high overall response rates (Sparano, 1999). However,
unacceptable degrees of congestive heart failure has been reported
in a subgroup of patients. In this context, it is of interest that
BRCA1-defective cells in vitro are resistant to both drugs,
suggesting that this treatment might be ineffective in breast
hereditary cancer patients. It has been reported that anticancer
drugs trigger apoptosis in various cancer cells, including solid
tumours, suggesting that apoptotic events are associated with the
antitumour activity of these drugs (Hickman, 1992; Seki et al,
2000). We have indeed found that the differences in cytotoxic
activity were paralleled by differential induction of apoptosis.
In conclusion, our findings support the hypothesis of a specific
pattern of chemosensitivity in BRCA1 breast hereditary carcino-
mas when compared with breast tumours arising in the sporadic
setting. To our knowledge, our study is the first report where the
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Figure 5 Full-length transfection of BRCA1 in HCC1937 (HCC1937/
WTBRCA1) induces resistance to CDDP and restores sensitivity to Dox and Tax. In
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seffect of BRCA1 inactivation and reconstitution on drug sensitivity
is evaluated in cells derived from a tumour arising in the BRCA1
hereditary setting. This appears to be of specific interest taking
into account that these tumours appear to displace a peculiar gene
expression profile as compared to BRCA2 and sporadic tumours
(Hedenfalk et al, 2001). The results obtained in BRCA1 full-length
transfected cells suggest that the BRCA1 gene product is a key
modulator of drug sensitivity in breast cancer cells in this specifc
setting and add novel information as compared to studies
performed on breast sporadic tumours. These data therefore,
support, the concept that inherited breast tumours are a different
form of disease, suggesting the intringuing possibility of tailored
treatment in this setting.
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